{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T08:49:20Z","timestamp":1774946960622,"version":"3.50.1"},"reference-count":56,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"name":"Merck"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Ther Adv Neurol Disord"],"published-print":{"date-parts":[[2026,3]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>\n                      Patient support programs (PSP) help initiate and maintain disease-modifying treatment (DMT) for people with multiple sclerosis (PwMS). adveva\n                      <jats:sup>\u00ae<\/jats:sup>\n                      (worldwide), Alcura Healthcare (Netherlands), and MS LifeLines\n                      <jats:sup>\u00ae<\/jats:sup>\n                      (US) are nurse\u2013pharmacy-led PSPs that collect clinical information, with consent, on PwMS receiving cladribine tablets (3.5\u2009mg\/kg over 2\u2009years followed by a 2-year treatment-free period per product label).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective:<\/jats:title>\n                    <jats:p>To evaluate initiation and completion of short courses of cladribine tablets treatment in Years 1 and 2 for PwMS and the frequency of subsequent treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design:<\/jats:title>\n                    <jats:p>Retrospective, multinational, observational study using real-world data from PSPs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>Clinical data from PSPs in Australia, Canada, Gulf, Latin America, Near East, Netherlands, UK, and US (December 2017\u2013December 2023) included prior DMT use, cladribine tablets initiation and completion (Years 1 and 2), and subsequent treatment after Year 2 for those with \u2a7e48\u2009months\u2019 follow-up.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      Across all PSPs, 22,082 PwMS initiated cladribine tablets (Australia,\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      \u2009=\u2009799; Canada,\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      \u2009=\u20093665; Gulf,\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      \u2009=\u2009258; Latin America,\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      \u2009=\u20091854; Near East,\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      \u2009=\u200986; Netherlands,\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      \u2009=\u2009681; UK,\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      \u2009=\u20092320; US,\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      \u2009=\u200912,418), of whom 70.9%\u201381.3% were female (mean age 34.2\u201349.1\u2009years). Most were DMT-experienced (Australia, no contribution to analysis; Canada, 100%; Gulf, 52.7%; Latin America, 57.7%; Near East, 86.0%; Netherlands, 81.4%; UK, 30.0%; US, 79.5%) with oral DMTs most commonly used (36.5%\u201369.3%). In PwMS with \u2a7e18\u2009months\u2019 follow-up, \u2a7e82.8% initiated Year 2 treatment at a mean of 12.4 (\u00b13.8) to 13.9 (\u00b13.5)\u2009months after initiating Year 1 treatment. Of those commencing Year 2 treatment, \u2a7e93.6% completed it. Additional treatment with cladribine tablets beyond 48\u2009months was administered in a small proportion of PwMS: Canada, 5.6%; Latin America, 4.3%; Netherlands, 3.8%; and UK, 1.8%.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Cladribine tablets adherence was high, with most PwMS completing short-course cladribine tablets treatment in Years 1 and 2. Of those with \u2a7e48\u2009months\u2019 follow-up, only a small proportion received additional cladribine tablets treatment.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/17562864261426842","type":"journal-article","created":{"date-parts":[[2026,3,29]],"date-time":"2026-03-29T04:08:13Z","timestamp":1774757293000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["Insights into adherence to cladribine tablets in the real world in multiple countries: results from patient support programs"],"prefix":"10.1177","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5519-6088","authenticated-orcid":false,"given":"Jiwon","family":"Oh","sequence":"first","affiliation":[{"name":"Division of Neurology, Department of Medicine, St Michael\u2019s Hospital, University of Toronto, Toronto, ON, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mavis","family":"Ayer","sequence":"additional","affiliation":[{"name":"Southampton General Hospital, Southampton, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5436-5804","authenticated-orcid":false,"given":"Raed","family":"Alroughani","sequence":"additional","affiliation":[{"name":"Division of Neurology, Department of Medicine, Amiri Hospital, Sharq, Kuwait"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samar","family":"Farouk","sequence":"additional","affiliation":[{"name":"Division of Neurology, Department of Medicine, Ibn Sina Hospital, Kuwait City, Kuwait"},{"name":"Department of Neuropsychiatry, Faculty of Medicine, Minia University, Minia, Egypt"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mounir","family":"Khoury","sequence":"additional","affiliation":[{"name":"Division of Neurology, Department of Internal Medicine, Saint George Hospital University Medical Center, University of Balamand, Beirut, Lebanon"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sabrina","family":"de Souza","sequence":"additional","affiliation":[{"name":"Merck Healthcare KGaA, Darmstadt, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michela","family":"Bossolasco","sequence":"additional","affiliation":[{"name":"EMD Serono, Inc., Mississauga, ON, Canada, an affiliate of Merck KGaA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kate","family":"Morgan","sequence":"additional","affiliation":[{"name":"Merck Serono Ltd, Feltham, UK, an affiliate of Merck KGaA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Negrotto","sequence":"additional","affiliation":[{"name":"Merck S.A., Buenos Aires, Argentina, an affiliate of Merck KGaA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tracey","family":"Quinn","sequence":"additional","affiliation":[{"name":"Merck Healthcare Pty. Ltd, Macquarie Park, NSW, Australia, an affiliate of Merck KGaA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amir","family":"Boshra","sequence":"additional","affiliation":[{"name":"Merck Serono Middle East FZ-Ltd, Dubai, United Arab Emirates, an affiliate of Merck KGaA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph","family":"Youssef","sequence":"additional","affiliation":[{"name":"Merck Serono Middle East FZ-Ltd, Dubai, United Arab Emirates, an affiliate of Merck KGaA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Murad","family":"Al-Naqshbandi","sequence":"additional","affiliation":[{"name":"Merck Serono Middle East FZ-Ltd, Dubai, United Arab Emirates, an affiliate of Merck KGaA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kelly","family":"MacDonald","sequence":"additional","affiliation":[{"name":"EMD Serono Inc., Boston, MA, USA, an affiliate of Merck KGaA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4281-6759","authenticated-orcid":false,"given":"Meritxell","family":"Sabid\u00f3","sequence":"additional","affiliation":[{"name":"Merck Healthcare KGaA, Frankfurter Str. 250, Darmstadt 64293, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeffrey M.","family":"Muir","sequence":"additional","affiliation":[{"name":"Market Access &amp; Health Economics, Cytel, Inc., Toronto, ON, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5866-2419","authenticated-orcid":false,"given":"Berenice","family":"Silva","sequence":"additional","affiliation":[{"name":"Department of Neurology, Italian Hospital of Buenos Aires, Buenos Aires, Argentina"},{"name":"Division of Neurology, University Center for Multiple Sclerosis, Faculty of Medicine, Ramos Mej\u00eda Hospital, University of Buenos Aires, Buenos Aires, Argentina"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2026,3,28]]},"reference":[{"key":"e_1_3_4_2_2","doi-asserted-by":"publisher","DOI":"10.1177\/1352458520970841"},{"key":"e_1_3_4_3_2","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12051870"},{"key":"e_1_3_4_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2020.102189"},{"key":"e_1_3_4_5_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000000560"},{"key":"e_1_3_4_6_2","doi-asserted-by":"publisher","DOI":"10.1136\/pn-2024-004228"},{"key":"e_1_3_4_7_2","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2022.824926"},{"key":"e_1_3_4_8_2","doi-asserted-by":"publisher","DOI":"10.1177\/1352458517727603"},{"key":"e_1_3_4_9_2","doi-asserted-by":"publisher","DOI":"10.1177\/17562864251342855"},{"key":"e_1_3_4_10_2","unstructured":"European Medicines Agency. EPAR summary for the public: Mavenclad\u2014cladribine https:\/\/www.ema.europa.eu\/en\/documents\/overview\/mavenclad-epar-summary-public_en.pdf (2017 accessed 20 October 2025)."},{"key":"e_1_3_4_11_2","unstructured":"Merck KGaA. Product monograph Mavenclad https:\/\/pdf.hres.ca\/dpd_pm\/00059092.PDF (2020 accessed 20 October 2025)."},{"key":"e_1_3_4_12_2","unstructured":"Merck KGaA. FDA approves MAVENCLAD\u00ae (cladribine) tablets as first and only short-course oral treatment for relapsing\u2013remitting and active secondary progressive multiple sclerosis https:\/\/www.emdgroup.com\/press-releases\/2019\/mar\/us\/Mavenclad-US.pdf (2019 accessed 20 October 2025)."},{"key":"e_1_3_4_13_2","doi-asserted-by":"publisher","DOI":"10.1177\/13524585211010294"},{"key":"e_1_3_4_14_2","doi-asserted-by":"publisher","DOI":"10.1177\/13524585231161494"},{"key":"e_1_3_4_15_2","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-021-01865-w"},{"key":"e_1_3_4_16_2","doi-asserted-by":"publisher","DOI":"10.1177\/13524585211049392"},{"key":"e_1_3_4_17_2","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-019-01140-z"},{"key":"e_1_3_4_18_2","article-title":"Early MRI outcomes in participants with a first clinical demyelinating event at risk of multiple sclerosis in the ORACLE-MS study","volume":"7","author":"Freedman MS","year":"2021","unstructured":"Freedman MS, Coyle PK, Comi G, et al. Early MRI outcomes in participants with a first clinical demyelinating event at risk of multiple sclerosis in the ORACLE-MS study. Mult Scler J Exp Transl Clin 2021; 7: 2055217321990852.","journal-title":"Mult Scler J Exp Transl Clin"},{"key":"e_1_3_4_19_2","article-title":"The efficacy of cladribine tablets in CIS patients retrospectively assigned the diagnosis of MS using modern criteria: results from the ORACLE-MS study","volume":"3","author":"Freedman MS","year":"2017","unstructured":"Freedman MS, Leist TP, Comi G, et al. The efficacy of cladribine tablets in CIS patients retrospectively assigned the diagnosis of MS using modern criteria: results from the ORACLE-MS study. Mult Scler J Exp Transl Clin 2017; 3: 2055217317732802.","journal-title":"Mult Scler J Exp Transl Clin"},{"key":"e_1_3_4_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2020.102695"},{"key":"e_1_3_4_21_2","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000477"},{"key":"e_1_3_4_22_2","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000001187"},{"key":"e_1_3_4_23_2","doi-asserted-by":"publisher","DOI":"10.1177\/13524585231205962"},{"key":"e_1_3_4_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clineuro.2024.108249"},{"key":"e_1_3_4_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2023.104951"},{"key":"e_1_3_4_26_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10354-022-00931-4"},{"key":"e_1_3_4_27_2","doi-asserted-by":"publisher","DOI":"10.1097\/WNF.0000000000000598"},{"key":"e_1_3_4_28_2","doi-asserted-by":"publisher","DOI":"10.1111\/ene.16250"},{"key":"e_1_3_4_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2023.105052"},{"key":"e_1_3_4_30_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2022.104403"},{"key":"e_1_3_4_31_2","doi-asserted-by":"publisher","DOI":"10.2147\/CLEP.S480525"},{"key":"e_1_3_4_32_2","doi-asserted-by":"publisher","DOI":"10.1177\/1352458517726380"},{"key":"e_1_3_4_33_2","doi-asserted-by":"publisher","DOI":"10.2165\/11593310-000000000-00000"},{"key":"e_1_3_4_34_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2021.103385"},{"key":"e_1_3_4_35_2","doi-asserted-by":"publisher","DOI":"10.1177\/1756285616634247"},{"key":"e_1_3_4_36_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40120-024-00593-x"},{"key":"e_1_3_4_37_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40271-022-00582-y"},{"key":"e_1_3_4_38_2","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-020-01349-3"},{"key":"e_1_3_4_39_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40120-022-00422-z"},{"key":"e_1_3_4_40_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40120-022-00394-0"},{"key":"e_1_3_4_41_2","doi-asserted-by":"publisher","DOI":"10.1080\/14656566.2022.2106783"},{"key":"e_1_3_4_42_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2022.104459"},{"key":"e_1_3_4_43_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-023-11846-4"},{"key":"e_1_3_4_44_2","volume-title":"CAPT-ACPT 2022 conference","author":"On PV","unstructured":"On PV, Ng R, Khoudigian S, et al. Real-world data generation leveraging the patient support program infrastructure to gather data to supplement HTA for rare tumours: what constitutes quality real-world evidence? In: CAPT-ACPT 2022 conference, Toronto, ON, 17\u201318 October 2022. Toronto: Canadian Association for Population Therapeutics."},{"key":"e_1_3_4_45_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40263-022-00965-7"},{"key":"e_1_3_4_46_2","doi-asserted-by":"publisher","DOI":"10.2147\/PPA.S59496"},{"key":"e_1_3_4_47_2","doi-asserted-by":"publisher","DOI":"10.1017\/cjn.2015.325"},{"key":"e_1_3_4_48_2","doi-asserted-by":"publisher","DOI":"10.1111\/ene.16289"},{"key":"e_1_3_4_49_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2024.105704"},{"key":"e_1_3_4_50_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40120-024-00589-7"},{"key":"e_1_3_4_51_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2025.106724"},{"key":"e_1_3_4_52_2","doi-asserted-by":"publisher","DOI":"10.3389\/jpps.2023.11877"},{"key":"e_1_3_4_53_2","doi-asserted-by":"publisher","DOI":"10.3747\/co.26.5107"},{"key":"e_1_3_4_54_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2022.103792"},{"key":"e_1_3_4_55_2","doi-asserted-by":"publisher","DOI":"10.3390\/curroncol30010011"},{"key":"e_1_3_4_56_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmjresp-2023-001734"},{"key":"e_1_3_4_57_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10072-024-07763-7"}],"container-title":["Therapeutic Advances in Neurological Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/17562864261426842","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/17562864261426842","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/17562864261426842","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T07:46:24Z","timestamp":1774943184000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/17562864261426842"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":56,"alternative-id":["10.1177\/17562864261426842"],"URL":"https:\/\/doi.org\/10.1177\/17562864261426842","relation":{},"ISSN":["1756-2864","1756-2864"],"issn-type":[{"value":"1756-2864","type":"print"},{"value":"1756-2864","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3]]},"article-number":"17562864261426842"}}